Nurix Therapeutics, Inc. - NRIX
About Gravity Analytica
Recent News
- 06.13.2025 - Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 06.13.2025 - Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 06.12.2025 - EHA 2025 Clinical Data Update
- 06.12.2025 - EHA 2025 Clinical Data Update
- 06.12.2025 - Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobu
- 06.12.2025 - Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)
- 06.06.2025 - Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
- 06.06.2025 - Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
- 06.04.2025 - Jefferies Global Healthcare Conference
- 06.04.2025 - Jefferies Global Healthcare Conference